カテゴリ： GlobalData, アメリカ, 企業調査

Applied Genetic Technologies Corp (AGTC)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：Applied Genetic Technologies Corp (AGTC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8013087
◆発行会社（調査会社）：GlobalData
◆発行日：2017年11月27日
◆ページ数：68
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Applied Genetic Technologies Corp (AGTC) is a pharmaceutical company that offers development of eye disease cures. The company develops treatments for patients that have diseases caused by broken genes. It provides products such as x-linked retinoschisis, achromatopsia, x-linked retinitis pigmentosa, alpha-1 antitrypsin deficiency and macular degeneration, among others. AGTC’s achromatopsia offers treatment inherited conditions that are associated with visual acuity loss, extreme light sensitivity resulting in daytime blindness, and total loss of color discrimination. The company’s x-linked retinoschisis offers treatment in retinal degeneration affecting young males, presenting with poor vision by school age. It also provides ophthalmology development programs and proof-of-concept data in multiple indications. The company operates through its offices in Alachua and Cambridge, the US, and others. AGTC is headquartered in Alachua, Florida, the US.

Applied Genetic Technologies Corp (AGTC) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Applied Genetic Technologies Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Applied Genetic Technologies Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Applied Genetic Technologies Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Applied Genetic Technologies Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Applied Genetic Technologies Corp, Medical Devices Deals, 2011 to YTD 2017 10
Applied Genetic Technologies Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Applied Genetic Technologies Corp, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Applied Genetic Technologies Raises US$37.5 Million In Series B Financing 12
Applied Genetic Technologies Raises US$0.8 Million In Venture Financing 14
Partnerships 15
Applied Genetic Tech Enters into R&D Agreement with Bionic Sight 15
Applied Genetic Technologies Enters into Co-Development Agreement with BCM Families Foundation 16
Applied Genetic Technologies Enters into R&D Agreement with Synpromics 17
Licensing Agreements 18
Biogen Enters into Licensing Agreement with Applied Genetic Technologies 18
Applied Genetic Technologies Enters into Licensing Agreement with 4D Molecular Therapeutics 20
Equity Offering 21
Applied Genetic Tech Raises USD30 Million in Private Placement of Shares 21
Applied Genetic Completes Underwriters Exercise of Over-Allotment Option for Public Offering of Shares for USD34.5 Million 23
Applied Genetic Technologies Completes IPO For US$57.5 Million 25
Applied Genetic Technologies Corp – Key Competitors 27
Applied Genetic Technologies Corp – Key Employees 28
Applied Genetic Technologies Corp – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 30
Financial Announcements 30
Nov 07, 2017: AGTC Announces Financial Results and Business Update for the Quarter Ended September 30, 2017 30
Sep 13, 2017: AGTC Announces Financial Results and Business Update for the Quarter and Fiscal Year Ended June 30, 2017 32
May 10, 2017: AGTC Announces Financial Results and Business Update for the Quarter Ended March 31, 2017 34
Feb 08, 2017: AGTC Announces Financial Results and Business Update for the Quarter Ended December 31, 2016 37
Nov 08, 2016: AGTC Announces Financial Results and Business Update for the Quarter Ended September 30, 2016 39
Sep 12, 2016: AGTC Announces Financial Results and Business Update for the Quarter and Fiscal Year Ended June 30, 2016 42
May 09, 2016: AGTC Announces Financial Results for the Quarter Ended March 31, 2016 45
Feb 08, 2016: AGTC Announces Financial Results for the Quarter Ended December 31, 2015 47
Corporate Communications 48
Sep 05, 2017: AGTC Appoints Matthew Feinsod, M.D. as Interim Chief Medical Officer 48
Aug 02, 2017: AGTC Appoints William Sullivan as Chief Financial Officer, Andrew Ashe Named General Counsel 49
Nov 17, 2016: Applied Genetic Technologies appoints chief medical officer 50
Aug 18, 2016: AGTC Appoints Anne M. VanLent to its Board of Directors 51
Feb 19, 2016: AGTC Selected to the University of Florida’s 2016 Gator100 52
Product News 53
06/08/2017: AGTC Announces Topline Safety Data for X-Linked Retinoschisis Phase 1/2 Study 53
05/09/2017: AGTC and Collaborators Present New Data on the Natural History of X-Linked Retinoschisis at the Association for Research in Vision and Ophthalmology Annual Meeting 54
05/05/2016: Investigational Gene-Based Therapy for Alpha-1 Antitrypsin Deficiency Demonstrates Durable Response at Five Years 55
05/02/2016: Novel Investigational Gene-Based Therapy for X-Linked Retinitis Pigmentosa Demonstrates Functional Rescue of Photoreceptor Structure and Function in Canine Model 56
04/20/2016: AGTC Announces Publication of Safety and Biodistribution Data Supporting Future Clinical Studies of Novel Gene Therapy for Treating Achromatopsia 57
Product Approvals 58
Aug 10, 2017: AGTC Files Investigational New Drug Application for the Treatment of X-linked Retinitis Pigmentosa Caused by Mutations in the RPGR Gene 58
Aug 03, 2017: AGTC Announces U.S. FDA Orphan Drug Designation for Gene Therapy to Treat X-Linked Retinitis Pigmentosa 59
Oct 19, 2016: AGTC Files Investigational New Drug Application for the Treatment of Achromatopsia Caused by Mutations in the CNGA3 Gene 60
Jun 07, 2016: AGTC Announces Orphan Medicinal Product Designation in the European Union for Gene Therapy to Treat X-linked Retinitis Pigmentosa 61
Clinical Trials 62
Aug 07, 2017: Research Published in Molecular Therapy Identifies Optimal Gene-based Therapeutic Construct for X-Linked Retinitis Pigmentosa 62
Aug 02, 2016: AGTC and the Medical College of Wisconsin Announce Publication of Natural History Study Data Evaluating Residual Photoreceptor Cone Status in Patients with CNGB3-associated Achromatopsia 64
Apr 22, 2016: AGTC Announces Data Evaluating Novel AAV-Based Gene Therapy as a Potential Treatment for Leber Congenital Amaurosis (LCA) and Severe Early-Childhood-Onset Retinal Degeneration (SECORD) 65
Jan 20, 2016: AGTC Announces Data Evaluating Novel AAV-Based Gene Therapy as a Potential Treatment for Alpha-1 Antitrypsin Deficiency 66
Jan 07, 2016: AGTC Announces Preclinical Data Evaluating Cone-Specific Promoters for Use in Gene Therapy of Achromatopsia and Other Retinal Diseases 67
Appendix 68
Methodology 68
About GlobalData 68
Contact Us 68
Disclaimer 68

List of Tables
Applied Genetic Technologies Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Applied Genetic Technologies Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Applied Genetic Technologies Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Applied Genetic Technologies Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Applied Genetic Technologies Corp, Deals By Therapy Area, 2011 to YTD 2017 9
Applied Genetic Technologies Corp, Medical Devices Deals, 2011 to YTD 2017 10
Applied Genetic Technologies Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Applied Genetic Technologies Raises US$37.5 Million In Series B Financing 12
Applied Genetic Technologies Raises US$0.8 Million In Venture Financing 14
Applied Genetic Tech Enters into R&D Agreement with Bionic Sight 15
Applied Genetic Technologies Enters into Co-Development Agreement with BCM Families Foundation 16
Applied Genetic Technologies Enters into R&D Agreement with Synpromics 17
Biogen Enters into Licensing Agreement with Applied Genetic Technologies 18
Applied Genetic Technologies Enters into Licensing Agreement with 4D Molecular Therapeutics 20
Applied Genetic Tech Raises USD30 Million in Private Placement of Shares 21
Applied Genetic Completes Underwriters Exercise of Over-Allotment Option for Public Offering of Shares for USD34.5 Million 23
Applied Genetic Technologies Completes IPO For US$57.5 Million 25
Applied Genetic Technologies Corp, Key Competitors 27
Applied Genetic Technologies Corp, Key Employees 28
Applied Genetic Technologies Corp, Other Locations 29

★海外企業調査レポート[Applied Genetic Technologies Corp (AGTC)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Waste Management, Inc.：企業の戦略・SWOT・財務分析
    Waste Management, Inc. - Strategy, SWOT and Corporate Finance Report Summary Waste Management, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Synergy Pharmaceuticals Inc：企業の戦略的SWOT分析
    Synergy Pharmaceuticals Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Volta River Authority：企業の戦略的SWOT分析
    Volta River Authority - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Litgrid AB (LGD1L)：企業の財務・戦略的SWOT分析
    Litgrid AB (LGD1L) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • G1 Therapeutics Inc (GTHX)-製薬・医療分野：企業M&A・提携分析
    Summary G1 Therapeutics Inc (G1 Therapeutics), formerly G Zero Therapeutics Inc is a healthcare company that develops novel, and small molecule therapies. The company pipeline products include CDK4/6, trilaciclib G1T28 a drug candidate; G1T38 a potential best compound, and G1T48. It undertakes disco …
  • CMP Pharma Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary CMP Pharma Inc (CMP Pharma), formerly Carolina Medical Products Company Inc is a specialty pharmaceutical company that develops and manufactures generic prescription, non-prescription and skin care products. The company’s prescription products include SPS suspension, isoniazid oral solution …
  • RaQualia Pharma Inc (4579)：製薬・医療：M&Aディール及び事業提携情報
    Summary RaQualia Pharma Inc (RaQualia) is a drug development company that discovers and develops pharmaceutical compounds. The company offers products such as anidulafungin, ziprasidone, dalbavancin, 5-HT2B antagonist, motilin receptor agonist, potassium-competitive acid blockerand 5-HT4 partial ago …
  • NovaBay Pharmaceuticals Inc (NBY)：企業の財務・戦略的SWOT分析
    Summary NovaBay Pharmaceuticals Inc (NovaBay), formerly NovaCal Pharmaceuticals Inc is a biopharmaceutical company that discovers and develops eyecare products. The company’s products include skin and wound cleanser, daily lid and lash hygiene spray solutions, and cosetic procedures. Its daily lid a …
  • Select Medical Holdings Corp (SEM)：企業の財務・戦略的SWOT分析
    Summary Select Medical Holdings Corp (SMHC) is a healthcare service provider that offers outpatient rehabilitation services. The center provides long-term acute care services such as cardiac services, infectious disease treatment, medically complex treatment, neuro or post-trauma, pulmonary or venti …
  • Vertical Computer Systems Inc (VCSY)：企業の財務・戦略的SWOT分析
    Summary Vertical Computer Systems Inc (VCSY) is a technology company that develops and markets of application software, cloud-based and software services, internet core technologies, and intellectual property assets. The company provides products such as siteflash, responseflash, empath, snappnet, a …
  • Sensient Technologies Corp (SXT)：企業の財務・戦略的SWOT分析
    Sensient Technologies Corp (SXT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Pioneer Energy Services Corp (PESX)：企業の財務・戦略的SWOT分析
    Pioneer Energy Services Corp (PESX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Palred Technologies Limited：戦略・SWOT・企業財務分析
    Palred Technologies Limited - Strategy, SWOT and Corporate Finance Report Summary Palred Technologies Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • MMX Mineracao e Metalicos SA：企業の戦略・SWOT・財務分析
    MMX Mineracao e Metalicos SA - Strategy, SWOT and Corporate Finance Report Summary MMX Mineracao e Metalicos SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • InSightec Ltd：医療機器：M&Aディール及び事業提携情報
    Summary Insightec Ltd (InSightec), a subsidiary of Elbit Imaging Ltd, is a medical device company that develops and markets magnetic resonance imaging ultrasound based medical devices. The company offers products through divisions such as neurosurgery, urology, oncology and womens’ health. Its servi …
  • Abraxas Petroleum Corp Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    Abraxas Petroleum Corp Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary Abraxas Petroleum Corp (Abraxas) is an oil and gas company. The company offers exploration, production and development of oil and gas properties across the US. Its properties are located in Mi …
  • Saudi Arabian Oil Co (2222)：企業の財務・戦略的SWOT分析
    Saudi Arabian Oil Co (2222) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Entia Biosciences Inc (ERGO)：企業の財務・戦略的SWOT分析
    Summary Entia Biosciences Inc (EBI) is a biotechnology company that provides nutrigenomics solutions for organic health, beauty and agriculture. The company’s solution includes ErgoD2, mushroom dietary supplement, and multi joint support. It offers ErgoD2 solutions such as Ergo-D2-Hemo, Ergo-D2-FLEX …
  • Iconic Therapeutics Inc-製薬・医療分野：企業M&A・提携分析
    Summary Iconic Therapeutics Inc (Iconic Therapeutics) is a biopharmaceutical company that provides translation of scientific insight into breakthrough medicines. The company offers development of tissue factor in angiogenesis, inflammation, and metastasis that led to develop new approach to retinal …
  • Oki Electric Industry Co., Ltd.：企業の戦略・SWOT・財務情報
    Oki Electric Industry Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Oki Electric Industry Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆